StockDuty ← Dashboard Oct 27, 2026 05:40 AM ET
SignalFDA/Bio

Moderna (MRNA) Gets Phase 3 Melanoma Vaccine Validation At ESMO And NEJM

Moderna's Phase 3 melanoma vaccine validation at ESMO and NEJM signals major clinical catalyst.

What happened: Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data at ESMO 2026 for their individualized mRNA melanoma vaccine, intismeran, combined with KEYTRUDA. Why it matters: The data support expectations for oncology revenue and the individualized manufacturing process as a moat, and analysts point to regulatory filings, adjuvant melanoma approvals, and reimbursement as the next tests of real world uptake. Market: -3.2% today ($140.61), +33.1% YTD, 1.3x vol — as of 23:45 UTC Verified: Q3_2026 (Oct 29) revenue $17.3B vs $17.3B est; next print ~Jan 28
Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data at ESMO 2026 for their individualized mRNA melanoma vaccine, intismeran, combined with KEYTRUDA.
The data support expectations for oncology revenue and the individualized manufacturing process as a moat, and analysts point to regulatory filings, adjuvant melanoma approvals, and reimbursement as the next tests of real world uptake. Market: -3.2% today ($140.61), +33.1% YTD, 1.3x vol — as of 23:45 UTC Verified: Q3_2026 (Oct 29) revenue $17.3B vs $17.3B est; next print ~Jan 28
Sources